- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03477994
Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing CABG
Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing Coronary Artery Bypass Grafting
This prospective, randomised, double blinded, controlled clinical trial will be conducted in 147 patients between 60 yr and 70 yr , ASA physical status II and III, undergoing CABG. Patients will be randomly allocated to either dexmedetomidine or clonidine (control) groups .Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4
Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur. In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h.Primary end point of the study is the incidence of delirium.The secondary endpoints will be the the duration of extubation, the length of ICU stay, need for inotropic support or vasopressors, hospital stay , mean arterial blood pressure and heart rate , hospital mortality rate , all additional sedatives including overall doses of morphine and haloperidol the incidence of adverse events as bradycardia
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
After Ethics committee approval, and a written informed consent will be taken from every patient, . Patients with a history of mental illness, severe dementia, delirium or undergoing emergency procedures will be excluded.
Anesthesia management will be standardized to minimize any effect of anesthetic type on neurological outcomes. Premedication with midazolam will be limited to a maximum of 0.05 mg/kg.
Anesthesia will be induced with 12 μg/kg fentanyl, 5-7mg/kg thiopental sodium, and 0.15 mg/kg pancuronium and maintained with 1% to 2.0% isoflurane. The heart rate and blood pressure will be maintained within 20% of the baseline values. Anticoagulation will be achieved with heparin to maintain an activated clotting time above 480 s.The CPB circuit will be primed with 1.8 l lactated Ringer's solution and 50 ml of 20% mannitol. Management of CPB will include systemic temperature drift to 32 C, targeted mean perfusion pressure between 60 and 80 mmHg, and pump flow rates of 2.2 l/min/m2 . Myocardial protection will be achieved with antegrade cold blood cardioplegia. A 32-μ m filter (Avecor Affinity, USA)will be used in the arterial perfusion line. Before separation from CPB, patients will be rewarmed to 36 to 37C. After separation from CPB, heparin will be neutralized with protamine sulfate, 1 mg/100 U heparin, to reach an activated clotting time within 10% of baseline.All patients will be transferred to ICU after surgery. Patients will be randomly allocated to either dexmedetomidine or clonidine (control) groups according to a computer-generated randomization code, with allocation ratio 1:1 .Opaque sealed envelopes will be done according to the randomization schedule and opened by a physician not involved in the study . Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4
+4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable A four millilitres vial of dexmedetomidine ( 100 micrograms per ml)will be drawn up and diluted in 46 ml of normal saline.The infusion of dexmedetomidine will be continued for a maximum period of 24 h. Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.Dexmedetomidine infusion will not be discontinued before extubation. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur. In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h.
Five ampoules of clonidine(750 μg) was drawn up and diluted in 45ml of normal saline.
Opioids were titrated to reach pain score 3 out of 10. Pain will be assessed using a standard 10-cm visual analog scale (0, no pain; 10, worst and unbearable pain). Patients received 2 mg morphine as rescue analgesic.
Primary end point of the study is the incidence of delirium, which is defined as a disturbed level of consciousness that develops over a period of hours or days and fluctuates over time.
Delirium will be assessed preoperatively (baseline)and postoperatively, in ICU every 2 hours using the confusion assessment method (CAM) for ICU.(7) When patients are discharged from ICU to the ward, delirium will be assessed using CAM every 8 hours for the next 5 days. The CAM-ICU is used for both ventilated and extubated patients. It included a fourstep algorithm : (1) an acute onset of changes or fluctuations in the course of mental status, (2)inattention, (3) disorganized thinking, and (4) an altered level of consciousness. Patients are delirious if both (1) and (2) were found inanition to either feature (3)or (4). Patients are stated either CAM positive (delirium present) or CAM negative (delirium absent). Incidence of delirium was confirmed by the psychiatry consultant. The onset and duration of delirium will be also recorded. The CAM-ICU and CAM testers were involved in the study . IV haloperidol(2.5-5 mg PRN), will be used as a first-line treatment in delirious patients, a regular dose 1 mg ads until symptoms resolve.
The secondary endpoints will be the the duration of extubation, the length of ICU stay, need for inotropic support or vasopressors, hospital stay , mean arterial blood pressure and heart rate , hospital mortality rate , all additional sedatives including overall doses of morphine and haloperidol, finally the incidence of adverse events as bradycardia, heart block , the need for pacemaker , nausea and vomiting will be recorded as well.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Cairo, Egypt, 11566
- Ain shams university
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
60-70 yrs age ASA II, III Scheduled for CABG -
Exclusion Criteria:
History of mental illness Delirium or dementia patient refusal to participate Emergency procedures Any contraindications to study drugs
-
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: dexmedetomidine group
Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 +4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur. |
an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
Andre navn:
|
|
Sham-komparator: clonidine group
In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2
μg/kg/h if Richmond assessment sedation score from +1 to +4 Five ampoules of clonidine(750 μg) will be drawn up and diluted in 45ml of normal saline.
|
an infusion of 0.5μg/kg then 0.1-0.2
μg/kg/h if Richmond assessment sedation score from +1 to +4.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
the incidence of delirium
Tidsramme: every 4 hours in first day in ICU then every 8h for the next day, after discharge from ICU to the ward it will be checked every 8h for 5 days
|
disturbed level of consciousness that develops over a period of hours or days and fluctuates over time.
|
every 4 hours in first day in ICU then every 8h for the next day, after discharge from ICU to the ward it will be checked every 8h for 5 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
length of ICU stay
Tidsramme: 2 days
|
time to stay in ICU discharge to the ward
|
2 days
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Ayman Shoeb, professor, Ain shams university
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Psykiske lidelser
- Patologiske prosesser
- Sykdommer i nervesystemet
- Postoperative komplikasjoner
- Nevrologiske manifestasjoner
- Forvirring
- Nevroatferdsmanifestasjoner
- Nevrokognitive lidelser
- Delirium
- Emergence Delirium
- Fysiologiske effekter av legemidler
- Adrenerge midler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Antihypertensive midler
- Sentralnervesystemdepressiva
- Autonome agenter
- Agenter fra det perifere nervesystemet
- Analgetika
- Sensoriske systemagenter
- Analgetika, ikke-narkotisk
- Adrenerge alfa-2-reseptoragonister
- Adrenerge alfa-agonister
- Adrenerge agonister
- Hypnotika og beroligende midler
- Sympatolytika
- Dexmedetomidin
- Klonidin
Andre studie-ID-numre
- FMASU R 16
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Delirium ved fremvekst
-
Taipei City HospitalFullførtPRU (Platelet Reactivity Unit) | APT (antiplatelet terapi) | HOTPR (High on Treat Platelet Reactivity)Taiwan
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityAktiv, ikke rekrutterendeAdenokarsinom i bukspyttkjertelen | Stage III Pancreatic Cancer American Joint Committee on Cancer v8 | Stadium 0 bukspyttkjertelkreft American Joint Committee on Cancer v8 | Stadium I pankreaskreft American Joint Committee on Cancer v8 | Stadium IV bukspyttkjertelkreft American Joint Committee...Forente stater
-
Shaare Zedek Medical CenterUkjentCalmmax Cream on UP hos CKD-pasienter.Israel
-
DePuy OrthopaedicsFullførtTotal hofteprotese | Pinnacle metall-på-metall | Revidert Pinnacle Metal-on-Metal | Uønsket lokal vevsreaksjon | MetallionerForente stater
-
University of UtahNational Cancer Institute (NCI)FullførtUtmattelse | Stillesittende livsstil | Metastatisk prostatakarsinom | Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVA Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVB Prostata Cancer AJCC (American Joint Committee on Cancer) v8Forente stater
-
Duke UniversityHar ikke rekruttert ennåDelirium Forvirringstilstand | Hyperaktivt delirium | Delirium på intensivavdelingen | Agitert DeliriumForente stater
-
Efficacy Care R&D LtdHadassah Medical OrganizationUkjentDelirium | Delirium, årsak ukjent | Delirium av blandet opprinnelse | Delirium Forvirringstilstand | Delirium medikamentindusertIsrael
-
Hospital Israelita Albert EinsteinFullførtPasienter Emergency on-site Care by Mobile Emergency UnitBrasil
-
Oslo University HospitalUniversity of Melbourne; Norwegian Academy of MusicFullførtDelirium i alderdommen | Delirium av blandet opprinnelse | Delirium lagt på demens | Delirium ForvirringstilstandNorge
-
Sengkang General HospitalRekrutteringDelirium og postoperativ kognitiv dysfunksjon (POCD) | Delirium, postoperativt | Delirium - PostoperativtSingapore
Kliniske studier på Dexmedetomidine
-
Bahria International HospitalFullført
-
Cairo UniversityRekrutteringBupivakain | Intratekal dexmedetomidin | Kneortopedisk kirurgiEgypt
-
McGill University Health Centre/Research Institute...RekrutteringAnalgesi | Smerte, akutt | Nerveblokk | Øvre ekstremitetskirurgiCanada
-
Benha UniversityRekrutteringDelirium - PostoperativtEgypt
-
Peking University First HospitalRekrutteringDelirium | Dexmedetomidin | Postoperativ omsorg | Intensivavdeling | Eldre pasienter | EsketaminKina
-
Younes Ahmed YounesHar ikke rekruttert ennå
-
Sichuan Academy of Medical SciencesHar ikke rekruttert ennåSepsis | Septisk sjokk
-
Cairo UniversityUkjentSpinal anestesi VarighetEgypt
-
National Cancer Institute, EgyptRekrutteringSpinal anestesi | Dexmedetomidin | Fentanyl | Sarkomer | Bupivakain | Nedre ekstremitet | Amputasjon over kneet | IntratekalEgypt
-
Peking University First HospitalRekrutteringKirurgi | Generell anestesi | Dexmedetomidin | Kvalitet på gjenoppretting | EsketaminKina